Nymox Pharmaceutical Corporation NYMXF
Annual
Quarterly
FY2023 · ended Dec 31, 2023 · Revenue $0 · Filed Jun 3, 2025
Nymox Pharmaceutical Corporation (NYMXF) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. Free cash flow was -$2.6 million. As of Dec 31, 2024 it held $74,000 in cash and investments and $0 in total debt.
Revenue
$0
Net income
$-4.49M
+49.2% vs prior year
Operating cash flow
$-2.60M
+35.9% vs prior year
Free cash flow
$-2.60M
+35.9% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
102.04M
+7.9% vs prior year
Net cash
$74,000
FY 2024
Operating margin
-234400.0%
FY 2020
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NYMXF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Quebec Canada, Quebec, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1018735
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $5,000 |
| Operating income | -$4.3M | -$8.3M | -$6.7M | -$12.5M | -$11.7M |
| Net income | -$4.5M | -$8.8M | -$6.6M | -$12.5M | -$11.7M |
| Operating cash flow | -$2.6M | -$4.1M | -$5.2M | -$9.8M | -$10.0M |
| Free cash flow | -$2.6M | -$4.1M | — | — | -$10.1M |
| Total assets | $654,000 | $627,000 | $1.6M | $1.4M | $4.3M |
| Total liabilities | $7.4M | $3.8M | $2.1M | $1.9M | $2.2M |
| Stockholders' equity | -$6.8M | -$3.2M | -$482,000 | -$506,000 | $2.1M |
| Cash and investments | $74,000 | $70,000 | $1.4M | $830,000 | $3.6M |
| Total debt | $0 | $0 | $173,000 | $391,459 | $425,620 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F/A | Amended annual report (foreign issuer) | Sep 29, 2026 | Dec 31, 2025 |
| 20-F/A | Amended annual report (foreign issuer) | Sep 16, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Sep 14, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 7, 2026 | Aug 7, 2026 |
| 6-K | Current report (foreign issuer) | Jun 3, 2026 | Jun 2, 2026 |
All 408 Nymox Pharmaceutical Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.